Kintara Therapeutics

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

SAN DIEGO, July 1, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, today announced topline data results from the recurrent arm of its open-label, Phase 2 clinical study of its lead compound VAL-083 being conducted at the MD Anderson Cancer Center (MD Anderson) in Houston, Texas. The Phase 2 trial is a two-arm, biomarker-driven study testing VAL-083 in glioblastoma multiforme (GBM) patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene.

Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM

Dogness

Document Security Systems

LiveXLive Media

National CineMedia

TDH Hlds

Pixelworks

If you really want to take a walk on the wild side, there are several stocks to buy under $5. But be prepared for unpredictability.

7 Stocks to Buy Under $5 for Big Gains

Kintara Therapeutics Inc (NASDAQ:KTRA) (OTCMKTS:DMPWW) (FRA:3DM), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, has announced its addition to the Russell Microcap Index.  The company said its addition will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted on June 4.

Kintara Therapeutics set to join the Russell Microcap Index

SAN DIEGO, June 7, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced Kintara's addition to the Russell MicrocapÒ Index. This milestone will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the U.S. market opens on June 28, 2021 according to a preliminary list of additions posted June 4, 2021.

Kintara Therapeutics Set to Join Russell Microcap® Index

Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) announced it has enrolled the final patient in the adjuvant arm of its ongoing Phase 2 clinical study of VAL-083 as a treatment for glioblastoma multiforme (GBM), a cancer that begins in the brain.  The adjuvant arm of the study, conducted at the MD Anderson Cancer Center in Austin, has patients receive VAL-083 in place of standard-of-care temozolomide (TMZ) following surgery and chemoradiation TMZ.

Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for glioblastoma multiforme

SAN DIEGO, June 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has enrolled the final patient in the adjuvant arm of its ongoing Phase 2 clinical study of VAL-083 being conducted at the MD Anderson Cancer Center (MD Anderson). The adjuvant arm of the study investigates newly-diagnosed patients suffering from glioblastoma multiforme (GBM) receiving VAL-083 in place of standard of care temozolomide (TMZ) as adjuvant therapy following surgery and chemoradiation TMZ.

Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that Chief Executive Officer Saiid Zarrabian will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021. Mr. Zarrabian will deliver his corporate presentation on June 9 at 2:30 pm ET, Track 1.

Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

The stock price of Kintara Therapeutics, Inc. (Nasdaq: KTRA) increased by over 25% during intraday trading. This is why it happened.

KTRA Stock Price: Over 25% Increase Explanation

Kintara Therapeutics Inc (NASDAQ: KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research registrational Phase 2/3 trial for glioblastoma multiforme (GBM) has been activated. The trial, titled GBM AGILE, is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for newly diagnosed and recurrent GBM.

Kintara Stock Soars After Site Activation Update On Glioblastoma Trial

Kintara Therapeutics, Inc. (NASDAQ:KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated in 15 US sites as of May 14, 2021.  The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM.

Kintara Therapeutics, Inc. says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme has now been activated in 15 US sites

Analysts at Aegis Capital Corp rated Kintara Therapeutics Inc (NASDAQ:KTRA) a 'Buy,' while maintaining a $7 share target price on the company which develops new solid tumor cancer therapies. The San Diego, California-based clinical stage drug development company closed its fiscal third quarter with cash and equivalents of about $15.7 million.

Kintara Therapeutics draws Buy recommendation from Aegis Capital which maintains a $7 price target

Kintara Therapeutics Inc (NASDAQ:KTRA), which is focused on the development of new solid tumor cancer therapies, said it closed its fiscal third quarter with cash and cash equivalents of about $15.7 million. That capital, the company said, is expected to be sufficient to fund its planned operations to the second quarter of calendar year 2022.

Kintara Therapeutics ends fiscal 3Q with cash and cash equivalents of about $15.7M

SAN DIEGO, May 14, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2021 and provided a corporate update. Fiscal Third Quarter Highlights and Recent Developments Commenced patient recruitment of Kintara's VAL-083 arm of the glioblastoma multiforme (GBM) AGILE registrational study sponsored by the Global Coalition for Adaptive Research (GCAR).

Kintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update

Kintara Therapeutics Inc (NASDAQ:KTRA) has announced the appointment of corporate finance veteran Tamara Seymour to its board of directors. Seymour replaces John Liatos, who will continue in his role as Kintara's senior vice president of business development, the company noted, "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," Kintara CEO Saiid Zarrabian said in a statement.

Kintara Therapeutics appoints corporate finance veteran Tamara Seymour as its board director

SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development.

Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

Kintara Therapeutics Inc (NASDAQ:KTRA) has announced interim data from two Phase 2 clinical trials of its lead compound, VAL-083 for glioblastoma multiforme (GBM), which continue to demonstrate its potential as a "game-changing treatment option". The data were presented in two posters at the 2021 American Association for Cancer Research (AACR) annual meeting, which is taking place virtually from April 10 to April 15, 2021.

Kintara Therapeutics says interim Phase 2 study data on VAL-083 shows its potential as game-changing treatment option for GBM patients

SAN DIEGO, April 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or resistant to, current treatment regimens, today announced interim data results from two Phase 2 clinical trials evaluating VAL-083, the Company's lead compound, for the treatment of glioblastoma multiforme (GBM).  The data were presented in two posters at the 2021 American Association for Cancer Research (AACR) Annual Meeting, which is taking place virtually from April 10-15, 2021.

Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting

Kintara Therapeutics, Inc. Chief Executive Officer Saiid Zarrabian participated in the Benzinga Biotech Small Cap Conference held March 24-25, 2021.  Kintara Therapeutics, Inc. (NASDAQ: KTRA) a biopharmaceutical company based in San Diego, California, and focused on the development of new solid tumor cancer therapies, continues to lead in the cancer treatment industry space with developing new and innovative novel cancer therapies for patients with rare unmet medical needs.

Kintara Taking The Lead In Developing New And Innovative Rare Cancer Therapies

SAN DIEGO, March 10, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces that its Chief Executive Officer Saiid Zarrabian will participate in Maxim Group's 2021 Emerging Growth Virtual Conference taking place March 17-18, 2021.  Mr. Zarrabian will be a speaker on a panel discussing glioblastoma and, more specifically, chemo-based and/or DNA repair target solutions.

Kintara Therapeutics to Participate in Maxim Group's 2021 Emerging Growth Virtual Conference

Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) has hired cancer expert Dr Mario Lacouture to its Cutaneous Metastatic Breast Cancer (CMBC)-focused scientific advisory board.  It comes as the company prepares its REM-001 therapy for late-stage pivotal testing for the condition.

Kintara Therapeutics appoints Dr Mario Lacouture to its scientific advisory board for cutaneous metastatic breast cancer

Kintara Therapeutics Inc (NASDAQ: KTRA) has enrolled the final patient in the recurrent arm of its ongoing Phase 2 study evaluating VAL-083 for glioblastoma multiforme, the most aggressive form of brain cancer. The study's recurrent arm in 83 pre-treated patients with temozolomide (TMZ) is being conducted at the MD Anderson Cancer Center.

Kintara Therapeutics Concludes Enrollment In Recurrent Arm Of VAL-083 Mid-Stage Brain Cancer Study

Kintara Therapeutics Inc (NASDAQ:KTRA) announced Wednesday that it has enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical glioblastoma multiforme (GBM) study of its VAL-083 drug. The recurrent arm of the study addresses patients suffering from GBM who have been pre-treated with the drug temozolomide (TMZ) prior to disease recurrence, the company said.

Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for recurrent glioblastoma multiforme

Kintara Therapeutics Inc (NASDAQ:KTRA), the cancer-focused biopharma, said it has enough cash to fund its planned operations into the fourth quarter of calendar 2021, as the company posted its second-quarter results on Friday. Fiscal 2Q to end-December, 2020 was an "important period of progress", said the company, which is advancing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).

Kintara Therapeutics says it has enough cash to fund its planned operations into the fourth quarter of calendar 2021

Kintara Therapeutics (NASDAQ:KTRA) is currently down 7.64% to a price of $2.46. The stock's volume is currently 77.04 thousand, which is roughly 4.66% of its recent 30-day volume average of 1.66 million.

Why Kintara Therapeutics's Stock is Down During Today's Session

SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the first quarter ended September 30, 2020 and...

News for Kintara Therapeutics Stock (KTRA)